Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More News From Daily Transparent

Historians say Trump upends norms of presidential behavior

Jul 19, 2018

HELSINKI — Plenty of U.S. presidents have created commotion in their travels abroad, but none as much as President Donald Trump. The president's tumultuous trip across Europe, historians say, smashed the conventions of American leaders on the world stage. Trump's "America first" approach to foreign policy had him seeming to accept the word of a hostile power over his own intelligence agencies, insulting allies and sowing doubts about his commitment to the NATO alliance. "We've never had a president go abroad and not only lecture to our NATO allies, but also to embarrass them," said Russia expert William Pomeranz, deputy...

Tumult of Trump's Europe trip smashes presidential precedent

Jul 19, 2018

HELSINKI — Plenty of U.S. presidents have created commotion in their travels abroad, but none as much as President Donald Trump. The president's tumultuous trip across Europe, historians say, smashed the conventions of American leaders on the world stage. Trump's "America first" approach to foreign policy had him seeming to accept the word of a hostile power over his own intelligence agencies, insulting allies and sowing doubts about his commitment to the NATO alliance. "We've never had a president go abroad and not only lecture to our NATO allies, but also to embarrass them," said Russia expert William Pomeranz, deputy...

World markets turn lower ahead of comments by Fed chair

Jul 19, 2018

SINGAPORE — World markets turned lower on Tuesday as investors looked ahead to Federal Reserve Chairman Jerome Powell's testimony to Congress for clues on U.S. interest rates. KEEPING SCORE: Germany's DAX shed 0.2 percent to 12,537 and the CAC 40 in France was down 0.4 percent at 5,3889. The FTSE 100 index fell 0.1 percent to 7,589. U.S. stocks were poised for small losses ahead of the release of industrial production figures. Dow and S&P 500 futures were both down 0.1 percent. ASIA'S DAY: Most Asian indexes closed lower as tensions over U.S. trade actions rattled investors. Japan's benchmark Nikkei...

Asian stocks fall, weighed by tensions over US trade tariffs

Jul 19, 2018

SINGAPORE — Asian markets fell on Tuesday as mounting tensions over U.S. tariffs overshadowed data suggesting global growth was still on track. KEEPING SCORE: South Korea's Kospi lost 0.2 percent to 2,297.64 and Hong Kong's Hang Seng lost 1.0 percent to 28,247.53 in morning trading. The Shanghai Composite index tumbled 1.0 percent to 2,785.68. Australia's S&P/ASX 200 dropped 0.5 percent to 6,213.30. Japan's benchmark Nikkei 225 bucked the regional trend, gaining 0.4 percent to 22,692.82. Shares fell in Taiwan and Southeast Asia. WALL STREET: Most U.S indexes closed lower on Monday as investors bought banks but sold most other types...

Trump embraces longtime US foe Putin, doubting own intel

Jul 19, 2018

HELSINKI — In an extraordinary embrace of a longtime U.S. enemy, President Donald Trump on Monday openly questioned his own intelligence agencies' firm finding that Russia meddled in the 2016 U.S. election to his benefit, seeming to accept Russian President Vladimir Putin's insistence that Moscow's hands were clean. The reaction back home was immediate and visceral, among fellow Republicans as well as usual Trump critics. "Shameful," ''disgraceful," ''weak," were a few of the comments. Makes the U.S. "look like a pushover," said GOP Sen. Bob Corker of Tennessee. Trump's meeting with Putin in Helsinki was his first time sharing the...

Sign up now!